Salubrinal

For research use only. Not for use in humans.

目录号:S2923

Salubrinal Chemical Structure

CAS No. 405060-95-9

Salubrinal是一种选择性eIF2α去磷酸化抑制剂,可以抑制ER应激介导的细胞凋亡,无细胞试验中EC50约为15 μM。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2297.41 现货
RMB 1214.29 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Salubrinal发表文献17篇:

客户使用该产品的3个实验数据:

  • AngII (30 minutes)-induced Akt activation was attenuated by the ER stress inhibitors 4-PBA (5 mM, 2 hours), TUDCA (300 µg/ml, 1 hour), and salubrinal (30 µM, 1 hour) (n=5; *P<0.01 versus con, #P<0.05 versus Ang)

    J Am Soc Nephrol, 2015, 26(8):1839-54. . Salubrinal purchased from Selleck.

  • PC-3 and HCT-116 p53+/+ cells were treated with 3-AWA and/or salubrinal for the indicated time point. The protein-specific antibodies were used to analyze the expression of the given proteins through immunoblotting.

    Oncogenesis, 2017, 6(5):e341. Salubrinal purchased from Selleck.

  • HEK293 cells were transfected with or without Flag-VP1 for 24 h, then treated with d Salubrinal (Sal, 75 μM) for 8 h followed by immunoblot detection. All data in this figure represent the mean ± SEM of three independent experiments. *p<0.05; ***p<0.01.

    Neurotox Res, 2017, 31(2):204-217. Salubrinal purchased from Selleck.

产品安全说明书

PERK抑制剂选择性比较

生物活性

产品描述 Salubrinal是一种选择性eIF2α去磷酸化抑制剂,可以抑制ER应激介导的细胞凋亡,无细胞试验中EC50约为15 μM。
靶点
eIF2α [1]
(Cell-free assay)
体外研究

Salubrinal是一种选择性细胞复合体抑制剂,使真核翻译起始因子2亚基α(eIF2α)去磷酸化。Salubrinal抑制蛋白糖基化抑制剂Tunicamycin(TM)诱导的ER应激介导的细胞凋亡,这种作用具有剂量依赖性,半数有效浓度(EC50)为15 μM。Salubrinal在caspase-7加工过程中,也抑制TM诱导的DNA断裂,ER应激激活caspase-7。然而,Salubrinal不是一般的凋亡抑制剂。Salubrinal作用于PC12细胞,快速且强效诱导eIF2α磷酸化及其下游效应,包括下调cyclin D1和上调GADD34和CHOP,eIF2α磷酸化诱导GADD34和CHOP这两种蛋白质的表达。Salubrinal通过抑制PP1/GADD34复合体,而抑制eIF2α去磷酸化。Salubrinal通过抑制eIF2α去磷酸化,而抑制HSV复制,IC50为3μM。[1]Salubrinal增强非快速眼动(NREM)睡眠。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LP-1 cell NUWyboxOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWHJcohq[mm2aX;uJI9nKGi3bXHuJGxRNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkO3NVEzKM7:TR?= NUDiXJQyW0GQR1XS
human 697 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3;Yb2lvcGmkaYTpc44hd2ZiaIXtZY4hPjl5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz65PFc5QCEQvF2= M2PTZnNCVkeHUh?=
human ALL-PO cell NYHOdpkyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGFNVC2STzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNFg3PTVizszN MoThV2FPT0WU
human ML-2 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUDOeWpXUW6qaXLpeIlwdiCxZjDoeY1idiCPTD2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE43OTh|MzFOwG0> NXKzTm1VW0GQR1XS
human LB2241-RCC cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NU\pUVZ7UW6qaXLpeIlwdiCxZjDoeY1idiCOQkKyOFEuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND65PFU4OiEQvF2= M3rEWXNCVkeHUh?=
human Becker cell M4nUO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXTJcohq[mm2aX;uJI9nKGi3bXHuJGJm[2uncjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|k1ODFizszN Mom3V2FPT0WU
human NEC8 cell NF3jXmJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkfkTY5pcWKrdHnvckBw\iCqdX3hckBPTUN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj6wOVM{OSEQvF2= NV7Z[pg6W0GQR1XS
human Daudi cell NGrQSJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmXLTY5pcWKrdHnvckBw\iCqdX3hckBF[XWmaTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uN|M3QTlizszN NHLNR|lUSU6JRWK=
human MHH-PREB-1 cell MlzBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3XkemlvcGmkaYTpc44hd2ZiaIXtZY4hVUiKLWDSSWIuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwN{i4NVch|ryP M1zIfHNCVkeHUh?=
human NCI-H510A cell Mn31S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1raPGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NVBCKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yM{WzOUDPxE1? NFXxdnJUSU6JRWK=
human NCI-H720 cell M{jmN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3\0eGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3NlAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjV5Mk[4JO69VQ>? MVrTRW5ITVJ?
human MRK-nu-1 cell NFzGTFBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH34dlJKdmirYnn0bY9vKG:oIHj1cYFvKE2USz3ueU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py55NUG3NUDPxE1? M2CyNXNCVkeHUh?=
human LB2518-MEL cell NFPKVpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1;YbmlvcGmkaYTpc44hd2ZiaIXtZY4hVEJ{NUG4MW1GVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwOUezNlYh|ryP MVnTRW5ITVJ?
human BE-13 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH3m[o9KdmirYnn0bY9vKG:oIHj1cYFvKEKHLUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE4zPjh2IN88US=> NEjVOHFUSU6JRWK=
human A3-KAW cell MoH6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MojYTY5pcWKrdHnvckBw\iCqdX3hckBCOy2NQWegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlQ{Ojh7IN88US=> M1fjbXNCVkeHUh?=
human ST486 cell NE\RUFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYLmNmw2UW6qaXLpeIlwdiCxZjDoeY1idiCVVES4OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVgvPTN4ODFOwG0> M{jUcHNCVkeHUh?=
human ES8 cell M{Xx[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX\Pb4p1UW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlY1OzN7IN88US=> MX;TRW5ITVJ?
human HT cell MkXKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUXFXZF5UW6qaXLpeIlwdiCxZjDoeY1idiCKVDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuPVQyQDVizszN MYrTRW5ITVJ?
human HAL-01 cell NVnhdWxUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NG\2VmZKdmirYnn0bY9vKG:oIHj1cYFvKEiDTD2wNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvOzF3MEWg{txO Mn3BV2FPT0WU
human EB-3 cell Mm[0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYLw[4JGUW6qaXLpeIlwdiCxZjDoeY1idiCHQj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU43OjV5MjFOwG0> NWjjXlh1W0GQR1XS
human EW-1 cell MlvRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2K5VmlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuO|EzPCEQvF2= MlnBV2FPT0WU
human BL-41 cell NEe3SmRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnzFTY5pcWKrdHnvckBw\iCqdX3hckBDVC12MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuO|gxPDlizszN MknKV2FPT0WU
Ramos-2G6-4C10 cell M4rXO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWXZOlVTUW6qaXLpeIlwdiCxZjDoeY1idiCUYX3vd{0zTzZvNFOxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvQTB|MUWg{txO M1XMSnNCVkeHUh?=
human DOHH-2 cell NGTBVG5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVzPfWdmUW6qaXLpeIlwdiCxZjDoeY1idiCGT1jIMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC5{Mk[yJO69VQ>? MXfTRW5ITVJ?
MONO-MAC-6 cell NEjpV4FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmnSTY5pcWKrdHnvckBw\iCqdX3hckBOV06RLV3BR{03KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTBwNUS4N{DPxE1? MYTTRW5ITVJ?
human NKM-1 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYTJcohq[mm2aX;uJI9nKGi3bXHuJG5MVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUCuOlE6PiEQvF2= NFXSV5pUSU6JRWK=
human HEL cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFruWppKdmirYnn0bY9vKG:oIHj1cYFvKEiHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlYzPTJizszN Mke1V2FPT0WU
human 8-MG-BA cell NHK3N2JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1\DcWlvcGmkaYTpc44hd2ZiaIXtZY4hQC2PRz3CRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExNjl7OUmg{txO M1LSZXNCVkeHUh?=
human K-562 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXTsN2NlUW6qaXLpeIlwdiCxZjDoeY1idiCNLUW2NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNjBzOUGg{txO Mnj4V2FPT0WU
human LXF-289 cell MlO2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWrJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU4yPTR5IN88US=> MnHMV2FPT0WU
human HC-1 cell NHLu[2ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGhENTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMT6xOVQ4KM7:TR?= MWnTRW5ITVJ?
human MC116 cell MlXaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoDmTY5pcWKrdHnvckBw\iCqdX3hckBOSzFzNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxMlIxPzNizszN M3[xUnNCVkeHUh?=
human TE-12 cell Mnn0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1nXZmlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU4{OzV5IN88US=> MYHTRW5ITVJ?
human BV-173 cell NXXkO5JMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3;2Z2lvcGmkaYTpc44hd2ZiaIXtZY4hSlZvMUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvPTB{MTFOwG0> NESyVmdUSU6JRWK=
human NCCIT cell M1TzbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmLZTY5pcWKrdHnvckBw\iCqdX3hckBPS0OLVDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxMlYxOzlizszN MUfTRW5ITVJ?
human CESS cell MorFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3rVc2lvcGmkaYTpc44hd2ZiaIXtZY4hS0WVUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxMlY3PjJizszN Mne2V2FPT0WU
human HUTU-80 cell M3W5N2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Moq2TY5pcWKrdHnvckBw\iCqdX3hckBJXVSXLUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvPjdyNDFOwG0> M362R3NCVkeHUh?=
human IST-SL2 cell M2DIUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUHJcohq[mm2aX;uJI9nKGi3bXHuJGlUXC2VTEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU44PzB2IN88US=> M{H5TXNCVkeHUh?=
human ATN-1 cell MoXoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHjydoVKdmirYnn0bY9vKG:oIHj1cYFvKEGWTj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVIvODJ{NjFOwG0> NXHEd2RPW0GQR1XS
human HCC1599 cell MojhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVrJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF3OUmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNk4yODl2IN88US=> NWnHZmk4W0GQR1XS
human NTERA-S-cl-D1 cell M13ncGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWjJcohq[mm2aX;uJI9nKGi3bXHuJG5VTVKDLWOtZ4wuTDFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMj64PFg5KM7:TR?= MVrTRW5ITVJ?
human EVSA-T cell M{m5eGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYPobmtVUW6qaXLpeIlwdiCxZjDoeY1idiCHVmPBMXQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOi57MkC0JO69VQ>? M4XKZ3NCVkeHUh?=
human NALM-6 cell NH6xXYdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2GwNWlvcGmkaYTpc44hd2ZiaIXtZY4hVkGOTT22JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvKEmFNUC9NVMvODl{OTFOwG0> NWP5flV{W0GQR1XS
human KMOE-2 cell NWXRXnU5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3TRW2lvcGmkaYTpc44hd2ZiaIXtZY4hU02RRT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVMvOTB7MjFOwG0> NY\0OWZsW0GQR1XS
human HL-60 cell M2Di[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlPqTY5pcWKrdHnvckBw\iCqdX3hckBJVC14MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGzMlM{ODhizszN NFnsTY1USU6JRWK=
human D-542MG cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoPYTY5pcWKrdHnvckBw\iCqdX3hckBFNTV2Ml3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVMvPDNyNjFOwG0> MU\TRW5ITVJ?
human L-363 cell M2[wV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2HJTGlvcGmkaYTpc44hd2ZiaIXtZY4hVC1|NkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN{42PTh|IN88US=> NFLhV|dUSU6JRWK=
human CMK cell M{Cyc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NU\lN2RMUW6qaXLpeIlwdiCxZjDoeY1idiCFTVugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN{44PDN4IN88US=> NH\lblVUSU6JRWK=
human IMR-5 cell Ml3lS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWHXSHczUW6qaXLpeIlwdiCxZjDoeY1idiCLTWKtOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE{Njd6NEmg{txO NHrTUohUSU6JRWK=
human A101D cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXvJcohq[mm2aX;uJI9nKGi3bXHuJGEyODGGIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUOuPFIxPyEQvF2= M4T0d3NCVkeHUh?=
human MOLT-16 cell NHHaZW1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXXJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN{46PjZ3IN88US=> MoW5V2FPT0WU
human LU-139 cell M172ZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn;ITY5pcWKrdHnvckBw\iCqdX3hckBNXS1zM{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE4xPDR2IN88US=> NV3tRoxyW0GQR1XS
human OVCAR-4 cell MljUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXHhbJNGUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTRwN{[wOEDPxE1? MYHTRW5ITVJ?
human BC-3 cell NEO2TIhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGn4SmJKdmirYnn0bY9vKG:oIHj1cYFvKEKFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE44QTh{IN88US=> MkDZV2FPT0WU
PC12 cells MofSSpVv[3Srb36gZZN{[Xl? NILwS4dEgXSxcILveIVkfGm4ZTDhZ5Rqfmm2eTDvckBz[XRidIXubYNidXmlaX6geJJm[XSnZDDyZZQheGinb3Podo9ud2O7dH;tZUBk\WyuIHzpcoUhWENzMjDmdo9uKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IFXu[I9xdGG|bXnjJJJmfGmldXz1cUB{fHKnc4OsJGVEPTB;MUWg{txO NGm1UGgyPjByMkK4PC=>
human D-336MG cell NGexV|RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnTDTY5pcWKrdHnvckBw\iCqdX3hckBFNTN|Nl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVUvOTF|NDFOwG0> NXPX[4hsW0GQR1XS
human BC-1 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkjYTY5pcWKrdHnvckBw\iCqdX3hckBDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUWuNVk5KM7:TR?= M{TjOHNCVkeHUh?=
human KE-37 cell NGrQXGtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYPJcohq[mm2aX;uJI9nKGi3bXHuJGtGNTN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUWuNlgzPCEQvF2= MWnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
ATF4 ; 

PubMed: 27729194     


OVCAR10 cells were incubated with sub-lethal dose of Salubrinal [20 μM] for 1, 3, 6, 12, 24 and 48 h. Whole cell lysates were subjected to Western blot analysis and probed with the above antibodies.

HSF1 / p-HSF1 / ATF3 / c-fos / NFATc1 / RelA ; 

PubMed: 27189267     


The accumulation of cellular transcription factors in nucleus was analyzed after treatment with salubrinal for 4 hours.

GRP78 / p-eIF2α / CHOP ; 

PubMed: 24525736     


HepG2 cells were treated with salubrinal at the indicated dosages for 24 h. Total proteins were harvested and subjected to western blotting analysis of GRP78, P-eIF2α, CHOP and β-actin. 

27729194 27189267 24525736
体内研究 Salubrinal处理小鼠角膜感染的模型,抑制HSV复制。与对照组比,Salubrinal局部处理,显著降低感染动物眼拭子中恢复的病毒滴度。[1]Salubrinal脑室内给药处理,显著改变稳态睡眠响应。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
- 合并
  • Cell lines: PC12
  • Concentrations: 0-100 μM
  • Incubation Time: 48 小时
  • Method: PC12细胞按每孔5000个接种在383孔板中,孔中为含3μg/ml TM 的40μL无酚红培养基,诱导ER应激。通过自动化针转移将100 nL DiverSet E (5 mg/mlin DMSO) 或美国国家癌症研究所(NCI) 结构多样性设置和开放性收集 (10 mM,溶于DMSO) (NCI)加入到孔中。48小时后,通过发光ATP实验测定细胞活力。每组实验板上DMSO和zVAD.fmk处理的孔分别作为阴性和阳性对照,缓解ER应激诱导的ATP损耗。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 8周大的雄性CD-1远交系小鼠
  • Dosages: 75μM
  • Administration: 角膜上滴定
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 95 mg/mL (197.99 mM)
Ethanol 2 mg/mL (4.16 mM)
Water Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 479.81
化学式

C21H17Cl3N4OS

CAS号 405060-95-9
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
Tags: 购买Salubrinal | Salubrinal供应商 | 采购Salubrinal | Salubrinal价格 | Salubrinal生产 | 订购Salubrinal | Salubrinal代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID